摘要
Background and study aims: To identify the roles and interaction of farnesoid X receptor (FXR) and peroxisome proliferator activated receptors (PPARs) in Non-alcoholic fatty liver disease (NAFLD) pathogenesis. @@@ Material and Methods: 16 C57/BL male FXR knockout (KO) mice and sex- and age-matched C57/BL wild type mice were received either standard rodent chow or high-fat and sucrose diet (Blank control, NAFLD, FXR KO and FXR KO NAFLD) for 8 weeks. After that, all mice were sacrificed. Liver tissues and blood samples were collected for laboratory and RT-PCR examination. @@@ Results: NAFLD, FXR KO and FXR KO NAFLD mouse models were successful established. Compared with blank control, FXR and PPAR-alpha mRNA expression decreased significantly (P < 0.05), PPAR-beta expression increased slightly (P > 0.05), PPAR-gamma expression increased significantly in NAFLD (P < 0.05). Slight increased PPAR-alpha mRNA expression (P > 0.05) and markedly decreased APAR-beta and PPAR-gamma expression (P < 0.05) were found in FXR KO. Compared with FXR KO group, there was a slight increase in APAR-alpha and PPAR-beta mRNA expression (P > 0.05) and significant increase in PPAR-gamma expression (P < 0.05) in FXR KO NAFLD group. Comparison with NAFLD, PPAR-alpha mRNA expression increased slightly (P > 0.05), APAR-beta and PPAR-gamma expression decreased significantly (P < 0.05) in FXR KO NAFLD. @@@ Conclusion: FXR and PPARs interaction may play important roles in NAFLD pathogenesis.
学科与关键词
- A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)Zhou, Shipeng; You, Huimin; Qiu, Shuting; Yu, Dawei; Bai, Yan; He, Jincan; Cao, Hua; Che, Qishi; Guo, Jiao*; Su, Zhengquan*Biomedicine and Pharmacotherapy, 2022, 154: 113577.被引 16
- Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitroZheng, Yi; Zhao, Jian; Miao, Deyu; Xu, Tingting; Wang, Liziniu; Liu, Changhui; Gao, Yong; Yu, Lili; Shen, Chuangpeng*Biomedicine and Pharmacotherapy, 2023, 164: 114957.被引 1
- Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXRGuo, Jingyi; Huang, Shangyi; Yi, Qincheng; Liu, Naihua; Cui, Tianqi; Duan, Siwei; Chen, Jiabing; Li, Jiayu; Li, Jun; Wang, Lei*; Gao, Yong*; Nie, Guangning*ACS OMEGA, 2023, 8(29): 26158-26169.
